Latest Depression News

Red Hawk Mining has issued a supplementary target's statement endorsing FMG’s increased $1.20 per share takeover offer, with FMG now holding a commanding 78% stake. The directors urge shareholders to accept the offer ahead of the March 3 closing date, citing the absence of superior proposals.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Newfield Resources Limited reports a strategic pivot for its Tongo Diamond Mine, engaging a joint development partner to reduce costs and delay bulk sampling amid a depressed diamond market.

Sultan Resources reports steady progress in its Western Australia gold and Canadian lithium projects while pausing nickel drilling due to market conditions, supported by a recent capital raise.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Reedy Lagoon Corporation reports promising soil sampling results at its Burracoppin Gold project while seeking partners for its iron venture amid challenging market conditions.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Newfield Resources clarifies its $10 million loan facility status, postpones key sampling work, and updates on ongoing dispute with Octea Limited, signaling cautious navigation through financial and operational challenges.

Zimplats' December quarter report reveals a decline in mined and milled volumes alongside increased cash costs per 6E ounce, even as key expansion projects advance steadily.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.